Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer.

Karasinska JM, Topham JT, Kalloger SE, Jang GH, Denroche RE, Culibrk L, Williamson LM, Wong HL, Lee MKC, O'Kane GM, Moore RA, Mungall AJ, Moore MJ, Warren C, Metcalfe A, Notta F, Knox JJ, Gallinger S, Laskin J, Marra MA, Jones SJM, Renouf DJ, Schaeffer DF.

Clin Cancer Res. 2019 Sep 3. doi: 10.1158/1078-0432.CCR-19-1543. [Epub ahead of print]

PMID:
31481506
2.

Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.

Jiang SH, Li J, Dong FY, Yang JY, Liu DJ, Yang XM, Wang YH, Yang MW, Fu XL, Zhang XX, Li Q, Pang XF, Huo YM, Li J, Zhang JF, Lee HY, Lee SJ, Qin WX, Gu JR, Sun YW, Zhang ZG.

Gastroenterology. 2017 Jul;153(1):277-291.e19. doi: 10.1053/j.gastro.2017.03.008. Epub 2017 Mar 15.

PMID:
28315323
3.

Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.

Zhao L, Zhao H, Yan H.

BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8.

4.

Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.

McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.

Gastroenterology. 2019 Sep;157(3):823-837. doi: 10.1053/j.gastro.2019.05.004. Epub 2019 May 9.

5.

Pancreatic cancer survival analysis defines a signature that predicts outcome.

Raman P, Maddipati R, Lim KH, Tozeren A.

PLoS One. 2018 Aug 9;13(8):e0201751. doi: 10.1371/journal.pone.0201751. eCollection 2018.

6.

Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.

Dimitrakopoulos C, Vrugt B, Flury R, Schraml P, Knippschild U, Wild P, Hoerstrup S, Henne-Bruns D, Wuerl P, Graf R, Breitenstein S, Bond G, Beerenwinkel N, Grochola LF.

JAMA Surg. 2019 Jun 1;154(6):e190484. doi: 10.1001/jamasurg.2019.0484. Epub 2019 Jun 19.

PMID:
30942874
7.

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, Mroue R, Corson L, O'Brien T, Qing J, Sampath D, Merchant M, Yauch R, Manning G, Settleman J, Hatzivassiliou G, Evangelista M.

Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4410-7. doi: 10.1073/pnas.1501605112. Epub 2015 Jul 27.

8.

Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.

Follia L, Ferrero G, Mandili G, Beccuti M, Giordano D, Spadi R, Satolli MA, Evangelista A, Katayama H, Hong W, Momin AA, Capello M, Hanash SM, Novelli F, Cordero F.

Front Oncol. 2019 Feb 27;9:115. doi: 10.3389/fonc.2019.00115. eCollection 2019.

9.

P4HA1/HIF1α feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.

Cao XP, Cao Y, Li WJ, Zhang HH, Zhu ZM.

Biochem Biophys Res Commun. 2019 Aug 27;516(3):606-612. doi: 10.1016/j.bbrc.2019.06.096. Epub 2019 Jun 22.

PMID:
31239153
10.

Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms.

Peran I, Madhavan S, Byers SW, McCoy MD.

Clin Cancer Res. 2018 Aug 15;24(16):3813-3819. doi: 10.1158/1078-0432.CCR-18-0290. Epub 2018 May 8.

11.

Integrative analysis of gene expression profiles reveals specific signaling pathways associated with pancreatic duct adenocarcinoma.

Li J, Tan W, Peng L, Zhang J, Huang X, Cui Q, Zheng J, Tan W, Wu C, Lin D.

Cancer Commun (Lond). 2018 Apr 27;38(1):13. doi: 10.1186/s40880-018-0289-9.

12.

Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset.

Nicolle R, Raffenne J, Paradis V, Couvelard A, de Reynies A, Blum Y, Cros J.

Cancers (Basel). 2019 Jan 21;11(1). pii: E126. doi: 10.3390/cancers11010126.

13.

Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.

Janky R, Binda MM, Allemeersch J, Van den Broeck A, Govaere O, Swinnen JV, Roskams T, Aerts S, Topal B.

BMC Cancer. 2016 Aug 12;16:632. doi: 10.1186/s12885-016-2540-6.

14.

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.

Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM, Chan TA, Witkiewicz AK.

Clin Cancer Res. 2017 Aug 1;23(15):4429-4440. doi: 10.1158/1078-0432.CCR-17-0162. Epub 2017 Mar 27.

15.

MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.

Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.

Clin Cancer Res. 2012 Jan 15;18(2):534-45. doi: 10.1158/1078-0432.CCR-11-0679. Epub 2011 Nov 23.

16.

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.

Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MHA, Bavi P, Bartlett JMS, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.

JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.

17.

Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma.

Goh TS, Ha M, Lee JS, Jeong DC, Jung ES, Han ME, Kim YH, Oh SO.

Onco Targets Ther. 2019 Apr 15;12:2853-2859. doi: 10.2147/OTT.S202101. eCollection 2019.

18.

Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?

Ben-Aharon I, Elkabets M, Pelossof R, Yu KH, Iacubuzio-Donahue CA, Leach SD, Lowery MA, Goodman KA, O'Reilly EM.

Clin Cancer Res. 2019 Apr 1;25(7):2185-2193. doi: 10.1158/1078-0432.CCR-18-3042. Epub 2019 Jan 7.

19.

Glucose metabolic phenotype of pancreatic cancer.

Chan AK, Bruce JI, Siriwardena AK.

World J Gastroenterol. 2016 Mar 28;22(12):3471-85. doi: 10.3748/wjg.v22.i12.3471. Review.

20.

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.

Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet O, Pinault M, Guimaraes C, Nigri J, Loncle C, Lavaut MN, Garcia S, Tailleux A, Staels B, Calvo E, Tomasini R, Iovanna JL, Vasseur S.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2473-8. doi: 10.1073/pnas.1421601112. Epub 2015 Feb 9.

Supplemental Content

Support Center